Clinical Trial Update: Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study [Phase 2]

View source ↗

Summary

A multi-centre Phase II feasibility trial evaluating tucatinib, trastuzumab, and capecitabine with brain/spinal radiotherapy in patients with HER2-positive brea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leptomeningeal Metastasis

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Tukysa (tucatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Sunnybrook Health Sciences Centre | Conditions: HER2-positive Breast Cancer, LMD | Phase 2 | Status: RECRUITING